Neko Health Raises $700M Series C: Clinical Profitability and 100k Members

What happened?

Neko Health, the preventive health startup founded by Daniel Ek (co-founder of Spotify) and Hjalmar Nilsonne, has announced the closing of a $700 million Series C round. The Stockholm-based company has reached 100,000 members and is profitable at the individual clinic level, according to statements to Sifted. This round doubles the valuation reported in previous rounds, although the exact amount has not been disclosed. The capital injection comes from investors such as Lakestar, Atomico, and other top-tier funds, underscoring market confidence in the primary prevention model.

Why it matters

This round is one of the largest in the European digital health sector, surpassing even Babylon Health's $550 million round in 2021. Neko Health uses non-invasive 60-second body scanners that detect risks of cardiovascular diseases, type 2 diabetes, and certain cancers at early stages. The annual subscription model (price undisclosed but estimated between €200 and €500 per year) and expansion to the UK and US indicate that the concept of 'preventive health as a service' is gaining traction. Unlike traditional medical check-ups, which are reactive and costly, Neko offers a comprehensive and rapid assessment with a personalized digital report. Profitability at the individual clinic level is a significant milestone: it means each center covers its operating costs without relying on cross-subsidies. This contrasts with other digital health startups that burn cash to acquire users.

Consequences and context

Profitability at the clinic level suggests the unit economics work: each clinic generates enough subscription revenue to cover rent, staff, and equipment maintenance. However, the company as a whole is not profitable, as R&D, expansion, and corporate marketing costs are funded by external capital. The Series C will primarily be used to open new clinics in strategic cities in the UK and US, as well as to improve scanning technology and the AI algorithms that analyze data. Compared to other health startups, such as Forward Health (which also uses scanners but with a more expensive monthly membership model), Neko differentiates itself through its focus on primary prevention, its Swedish origin, and its emphasis on financial sustainability. Forward Health, for example, raised $225 million in 2021 but has struggled to scale due to the high costs of its premium clinics. Neko, in contrast, bets on a lighter, more standardized model. The backing of investors like Lakestar and Atomico reinforces confidence in the model, especially in an environment where digital health startup funding fell 30% in 2023 compared to the previous year, according to CB Insights.

What readers should know

Neko Health is not health insurance, but a complementary early detection service. Critics point out that long-term clinical evidence is still limited: the scanners identify biomarkers, but there are no studies showing a significant reduction in mortality or morbidity among users. The company plans to open more clinics in cities like London, New York, and San Francisco, where demand for preventive health services is high. For users, the service offers an annual scan that generates a detailed report with personalized recommendations, including lifestyle changes and referrals to specialists if necessary. The user experience is key: the appointment lasts about 30 minutes, with results available in the app within 24 hours. Neko is also developing a loyalty program that rewards members who maintain healthy habits, similar to corporate wellness programs. Regarding regulation, the company operates under EU medical device regulations (CE marking) and is in the process of obtaining FDA approval for the US, which could delay its American expansion until 2025.

"Neko Health is redefining healthcare by focusing on prevention, not reaction," noted a digital health analyst. "But the real challenge will be proving that its scanners actually save lives in the long run, not just detect anomalies that may not require intervention."

In summary, Neko Health's Series C validates the scalable prevention business model, but the true impact will be measured by long-term health outcomes and the company's ability to maintain profitability while growing. If it can sustain positive unit economics in new clinics and accumulate robust clinical data, it could become a global benchmark for preventive health. Otherwise, it risks being a passing fad in a sector where many startups have failed by scaling too fast. For now, the $700 million is a strong bet that prevention is the future of medicine.